IL-1 Signaling in obesity-induced hepatic lipogenesis and steatosis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Negrin, Kimberly A ^a   Flach, Rachel J Roth ^a   DiStefano, Marina T ^a   Matevossian, Anouch ^a   Friedline, Randall H ^a   Jung, Daeyoung ^a   Kim, Jason K ^a   Czech, Michael P ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE 2; ACYL COENZYME A DESATURASE; CELL DEATH INDUCING DFFA LIKE EFFECTOR A; CELL PROTEIN; CLODRONIC ACID; CRYOPYRIN; DIACYLGLYCEROL ACYLTRANSFERASE; FAS ANTIGEN; FATTY ACID SYNTHASE; GLYCOPROTEIN P 15095; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LIPOSOME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEAROYL COENZYME A DESATURASE 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL1B PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL FUNCTION; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; FOOD INTAKE; GENE EXPRESSION; GLUCOSE TOLERANCE; HEPATIC LIPOGENESIS; IL 1ALPHA GENE; IL 1BETA GENE; KUPFFER CELL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER WEIGHT; MACROPHAGE; MALE; METABOLIC PARAMETERS; MOUSE; NLRP3 GENE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TNF ALPHA GENE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COMPLICATION; DRUG EFFECTS; GENETICS; HUMAN; LIVER CELL; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; FATTY ACID SYNTHASE, TYPE I; FATTY LIVER; GENE EXPRESSION; HEPATOCYTES; HUMANS; INTERLEUKIN-1BETA; KUPFFER CELLS; LIPOGENESIS; MICE; MICE, OBESE; OBESITY; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION;

EID: 84921907856     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107265     Document Type: Article

References (62)

1. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
2. Zeyda M, Stulnig TM (2009) Obesity, inflammation, and insulin resistance-A mini-review. Gerontology 55: 379-386.
3. Guilherme A, Virbasius JV, Puri V, Czech MP (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367-377.
4. Anderson N, Borlak J (2008) Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60: 311-357.
5. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, et al. (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30: 1212-1218.
6. Szabo G, Csak T (2012) Inflammasomes in liver diseases. J Hepatol 57: 642-654.
7. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
8. Nov O, Kohl A, Lewis EC, Bashan N, Dvir I, et al. (2010) Interleukin-1beta may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation. Endocrinology 151: 4247-4256.
9. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, et al. (2008) Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 8: 301-309.
10. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, et al. (2005) IKKβeta links inflammation to obesity-induced insulin resistance. Nat Med 11: 191-198.
11. Wen H, Gris D, Lei Y, Jha S, Zhang L, et al. (2011) Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12: 408-415.
12. Feng B, Jiao P, Nie Y, Kim T, Jun D, et al. (2011) Clodronate liposomes improve metabolic profile and reduce visceral adipose macrophage content in diet-induced obese mice. PLoS One 6: e24358.
13. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, et al. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116: 115-124.
14. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-Alpha function. Nature 389: 610-614.
15. McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, et al. (2011) Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat dietinduced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 60: 1688-1698.
16. Bu L, Gao M, Qu S, Liu D (2013) Intraperitoneal Injection of Clodronate Liposomes Eliminates Visceral Adipose Macrophages and Blocks High-fat Dietinduced Weight Gain and Development of Insulin Resistance. AAPS J 15: 1001-1011.
17. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.
18. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA (2010) Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 21: 261-267.
19. Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, et al. (2008) Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44: 141-148.
20. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, et al. (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32: 1663-1668.
21. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K (2008) The antiinflammatory cytokine interleukin-1 receptor antagonist protects from highfat diet-induced hyperglycemia. Endocrinology 149: 2208-2218.
22. Lanthier N, Molendi-Coste O, Cani PD, van Rooijen N, Horsmans Y, et al. (2011) Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet. FASEB J 25: 4301-4311.
23. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, et al. (2010) The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 12: 593-605.
24. Clementi AH, Gaudy AM, van Rooijen N, Pierce RH, Mooney RA (2009) Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling. Biochim Biophys Acta 1792: 1062-1072.
25. Young JL, Mora A, Cerny A, Czech MP, Woda B, et al. (2012) CD14 deficiency impacts glucose homeostasis in mice through altered adrenal tone. PLoS One 7: e29688.
26. Berry MN, Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structural study. J Cell Biol 43: 506-520.
27. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
28. Bu L, Gao M, Qu S, Liu D (2013) Intraperitoneal Injection of Clodronate Liposomes Eliminates Visceral Adipose Macrophages and Blocks High-fat Dietinduced Weight Gain and Development of Insulin Resistance. AAPS J 15: 1001-1011.
29. Lee YS, Li P, Huh JY, Hwang IJ, Lu M, et al. (2011) Inflammation is necessary for long-Term but not short-Term high-fat diet-induced insulin resistance. Diabetes 60: 2474-2483.
30. Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and obesity. J Clin Invest 121: 2094-2101.
31. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, et al. (2011) Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332: 243-247.
32. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351.
33. Dixon LJ, Flask CA, Papouchado BG, Feldstein AE, Nagy LE (2013) Caspase-1 as a central regulator of high fat diet-induced non-Alcoholic steatohepatitis. PLoS One 8: e56100.
34. Grunfeld C, Soued M, Adi S, Moser AH, Dinarello CA, et al. (1990) Evidence for two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-Alpha. Endocrinology 127: 46-54.
35. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, et al. (2012) IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122: 3476-3489.
36. Lamacchia C, Palmer G, Bischoff L, Rodriguez E, Talabot-Ayer D, et al. (2010) Distinct roles of hepatocyte-And myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice. J Immunol 185: 2516-2524.
37. Dinarello CA (2010) Anti-inflammatory Agents: Present and Future. Cell 140: 935-950.
38. Dinarello CA (2009) Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 360: 2467-2470.
39. Isoda K, Sawada S, Ayaori M, Matsuki T, Horai R, et al. (2005) Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 280: 7002-7009.
40. Aouadi M, Tencerova M, Vangala P, Yawe JC, Nicoloro SM, et al. (2013) Gene silencing in adipose tissue macrophages regulates wholeβody metabolism in obese mice. Proc Natl Acad Sci U S A 110: 8278-8283.
41. Leroux A, Ferrere G, Godie V, Cailleux F, Renoud ML, et al. (2012) Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 57: 141-149.
42. Li S, Sun Y, Liang CP, Thorp EB, Han S, et al. (2009) Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res 105: 1072-1082.
43. Ikarashi M, Nakashima H, Kinoshita M, Sato A, Nakashima M, et al. (2013) Distinct development and functions of resident and recruited liver Kupffer cells/macrophages. J Leukoc Biol 94: 1325-1336.
44. Kinoshita M, Uchida T, Sato A, Nakashima M, Nakashima H, et al. (2010) Characterization of two F4/80-positive Kupffer cell subsets by their function and phenotype in mice. J Hepatol 53: 903-910.
45. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838.
46. Ferre P, Foufelle F (2010) Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12 Suppl 2: 83-92.
47. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, et al. (2010) Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 120: 3466-3479.
48. Miyazaki M, Flowers MT, Sampath H, Chu K, Otzelberger C, et al. (2007) Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrateinduced adiposity and hepatic steatosis. Cell Metab 6: 484-496.
49. Harada N, Oda Z, Hara Y, Fujinami K, Okawa M, et al. (2007) Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol Cell Biol 27: 1881-1888.
50. Mao J, DeMayo FJ, Li H, Abu-Elheiga L, Gu Z, et al. (2006) Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci U S A 103: 8552-8557.
51. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, et al. (2006) Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 116: 817-824.
52. Moschen AR, Molnar C, Enrich B, Geiger S, Ebenbichler CF, et al. (2011) Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med 17: 840-845.
53. Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, et al. (2011) Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol 55: 1086-1094.
54. Kamari Y, Werman-Venkert R, Shaish A, Werman A, Harari A, et al. (2007) Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 195: 31-38.
55. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, et al. (2011) IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 187: 4835-4843.
56. Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, et al. (1989) Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 125: 267-274.
57. Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JE, et al. (2010) Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-Activated receptor alpha activity. Hepatology 51: 511-522.
58. Gabay C, Gigley J, Sipe J, Arend WP, Fantuzzi G (2001) Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur J Immunol 31: 490-499.
59. Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, et al. (2003) Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52: 1104-1110.
60. Meier CA, Chicheportiche R, Juge-Aubry CE, Dreyer MG, Dayer JM (2002) Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-Activated receptor gamma. Cytokine 18: 320-328.
61. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, et al. (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39: 188-196.
62. Belfort R, Harrison SA, Brown K, Darland C, Finch J, et al. (2006) A placebocontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297-2307